ReachRxResearch
Home
Research
Sign Up
CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations
Back to Research Hub
  1. Home
  2. Research Hub
  3. CAR T cells for autoimmune diseases: 202…

CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations

The Lancet Rheumatology·October 5
RheumatologyPractice changingAutoimmune DiseaseNeurological Autoimmune DiseaseRheumatic DiseaseExpert Consensus / Clinical Practice GuidelinesCAR T-Cell TherapyMixed

Summary

View source

What was studied

An international expert panel (EBMT, ISCT, JACIE) updated their 2024 consensus recommendations on CAR T-cell therapy for severe, refractory autoimmune diseases — including rheumatic, neurological, haematological, and paediatric indications — covering patient selection, clinical management, follow-up, and immune monitoring.

Key findings

The 2026 update provides expert-based, disease-specific guidance across multiple autoimmune conditions, reflecting accumulated evidence since CAR T cells first emerged as a treatment option for autoimmune diseases in 2021; specific outcome data beyond expert consensus are not reported in the abstract.

Study limitations

Recommendations are expert consensus-based rather than derived from randomised controlled trials, limiting the strength of the evidence; the target diseases are heterogeneous, making uniform guidance difficult; and as 'living recommendations,' they may not yet reflect the most recently published trial data.

Clinical implications

Clinicians managing patients with severe, refractory autoimmune diseases should consult these updated EBMT–ISCT–JACIE recommendations for disease-specific guidance on when and how to use CAR T-cell therapy, including patient selection criteria and monitoring protocols.

Caveats

  • As 'living recommendations,' this 2026 update may itself be superseded quickly as the CAR T-cell autoimmune evidence base is rapidly evolving
  • The paediatric indications section covers a population with distinct safety and dosing considerations that may not be fully addressed by adult-derived evidence
  • These are consensus-based recommendations, not randomised trial data — the level of evidence supporting individual recommendations varies and may be low for rarer indications

Related Questions

Explore related topics

CAR T cell therapy for refractory autoimmune diseases patient selection criteriaCD19 CAR T cells systemic lupus erythematosus clinical outcomesEBMT guidelines CAR T cell management and follow-up autoimmune

Publication Details

Year
2026
Journal
The Lancet Rheumatology
Source
View article
Keep scrolling
More content below.
Up Next